샘플 요청 목록

 카트 문의
시장보고서
상품코드
1874663

세계의 에리스로포이에틴 제제 시장

Erythropoietin Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 179 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 에리스로포이에틴 제제 시장은 2030년까지 173억 달러에 달할 전망

2024년에 134억 달러로 추정되는 세계의 에리스로포이에틴 제제 시장은 2024-2030년의 분석 기간에 CAGR 4.3%로 성장하며, 2030년까지 173억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석 대상으로 한 부문의 하나인 에포에틴 알파는 4.5%의 CAGR을 기록하며, 분석 기간 종료까지 92억 달러에 달할 것으로 예측됩니다. 다베포에틴 알파 부문의 성장률은 분석 기간에 4.8%의 CAGR로 추정되고 있습니다.

미국 시장은 37억 달러로 추정되며, 중국은 4.0%의 CAGR로 성장할 것으로 예측됩니다.

미국의 에리스로포이에틴 제제 시장은 2024년에 37억 달러로 추정되고 있습니다. 세계 2위의 경제 규모를 자랑하는 중국은 2024-2030년의 분석 기간에 CAGR 4.0%로 추이하며, 2030년까지 27억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장 분석으로는 일본과 캐나다를 들 수 있으며, 분석 기간 중 각각 CAGR 4.2%, 3.5%로 성장할 것으로 예측됩니다. 유럽에서는 독일이 약 3.4%의 CAGR로 성장할 것으로 전망되고 있습니다.

세계 에리스로포이에틴 제제 시장 - 동향 및 성장 촉진요인 파악

에리스로포이에틴 제제가 현대 의료에서 중요한 이유는 무엇인가?

에리스로포이에틴(EPO) 제제는 만성콩팥병(CKD), 암, 기타 적혈구 생성 억제 질환에 따른 빈혈 치료에 매우 중요한 역할을 합니다. 이 약제들은 주로 신장에서 생성되어 골수에서 적혈구 생성을 촉진하는 천연 호르몬인 '에리스로포이에틴'을 모방합니다. 적혈구 수를 증가시킴으로써 에리스로포이에틴 제제는 조직에 산소 공급을 개선하고 피로를 감소시키며 환자의 전반적인 건강 상태를 개선합니다. 수년간 그 사용은 신장학, 종양학, 신경학, 심지어 스포츠 의학까지 확장되어 현대 의학에서 가장 다용도한 생물제제 중 하나가 되었습니다.

특히 고령화 사회에서 만성신장병(CKD) 및 암 관련 빈혈의 유병률이 증가함에 따라 에리스로포이에틴 제제 수요가 급증하고 있습니다. 또한 화학요법을 받는 환자들은 종종 심각한 빈혈을 경험하므로 치료 관련 부작용을 줄이기 위해 EPO 제제를 사용해야 합니다. 바이오기술의 발전에 따라 달베포에틴 알파, 메톡시 폴리에틸렌글리콜루에포에틴 베타 등 새로운 제제가 개발되어 반감기를 연장하고 투여 빈도를 줄인 새로운 제제가 개발되고 있습니다. 또한 바이오시밀러 에리스로포이에틴 제제는 브랜드 생물제제를 대체할 수 있는 비용 효율적인 대안으로 전 세계 환자들의 접근성 확대에 기여하고 있습니다. 전 세계에서 빈혈 관련 질환의 부담이 계속 증가하고 있는 가운데, 에리스로포이에틴은 효과적인 빈혈 관리의 근간이 되고 있습니다.

에리스로포이에틴 제제 시장은 혁신을 통해 어떻게 변화하고 있는가?

에리스로포이에틴 제제의 혁신은 보다 효율적이고 지속적이며 비용 효율적인 치료법의 필요성에 의해 추진되어 왔습니다. 가장 중요한 진전 중 하나는 반감기 연장 및 효능 향상을 특징으로 하는 2세대 및 3세대 EPO 제제의 개발입니다. 예를 들어 달베포에틴 알파는 당쇄를 추가하여 기존 재조합 인간 에리스로포이에틴(rHuEPO)에 비해 투여 빈도를 줄일 수 있게 되었습니다. 마찬가지로 메톡시 폴리에틸렌글리콜루에포에틴 베타는 작용 시간이 길어 잦은 주사의 필요성을 줄이고 환자의 순응도를 향상시킵니다. 이러한 차세대 약물은 특히 장기 치료가 필요한 만성신장질환(CKD) 및 암 환자의 빈혈 치료에 혁명을 일으키고 있습니다.

또 다른 큰 발전은 저산소 유도인자 프롤릴수산화효소 억제제(HIF-PHI)와 같은 대체 메커니즘으로 작용하는 적혈구 조혈자극인자(ESA)의 등장입니다. 이 경구용 약물은 기존의 EPO 주사와 달리 저산소 상태에 대한 신체의 자연적 반응을 모방하여 내인성 에리스로포이에틴의 생성을 자극합니다. 이 혁신은 특히 주사 요법을 견디지 못하는 CKD 환자들에게 새로운 치료의 길을 열어주었습니다. 또한 바이오시밀러 EPO 제제의 보급이 확대되면서 효능은 그대로 유지하면서 합리적인 가격의 대안이 제공되어 시장에 큰 변화를 가져오고 있습니다. 정부와 의료 서비스 프로바이더들이 비용 효율적인 치료 옵션을 찾는 가운데, 바이오시밀러는 시장 점유율을 더욱 확대할 것으로 예상되며, 전 세계에서 EPO 치료의 접근성을 높일 수 있을 것으로 기대됩니다.

에리스로포이에틴 제제 수요를 주도하는 치료 분야는?

에리스로포이에틴 제제는 여러 치료 영역에서 확고한 입지를 구축하고 있으며, 특히 신장학 및 종양학이 시장을 주도하고 있습니다. 신장 기능 저하에 따른 빈혈이 빈번하게 발생하는 CKD가 가장 큰 부문이며, CKD의 주요 위험 요인인 당뇨병과 고혈압의 유병률 증가에 따라 에리스로포이에틴 제제에 대한 수요는 지속적으로 증가하고 있습니다. 투석 치료나 신장이식을 받은 환자들도 충분한 적혈구 수치를 유지하고 심각한 빈혈 관련 합병증을 예방하기 위해 EPO 요법에 크게 의존하고 있습니다. 신장학 분야에서 이러한 약물에 대한 의존도는 CKD 관리의 중요한 구성 요소로 확고히 자리 잡고 있습니다.

종양학 분야도 에리스로포이에틴 제제 수요의 주요 견인차 역할을 하고 있습니다. 암 환자들은 화학요법으로 인한 골수 억제에 의해 빈혈이 발생하는 경우가 많기 때문입니다. EPO 제제를 사용함으로써 종양 전문의는 수혈의 필요성을 줄이고 환자의 삶의 질을 향상시키며 지속적인 암 치료를 지원할 수 있습니다. 또한 에리스로포이에틴 제제는 신경학을 포함한 다른 의료 분야에서도 주목받고 있으며, 뇌졸중 및 신경 퇴행성 질환에 대한 신경 보호 효과에 대한 탐색이 진행되고 있습니다. 일부 연구에서는 뇌 손상 후 인지기능 회복을 촉진할 수 있는 가능성을 시사하고 있으며, 새로운 응용 가능성을 열어두고 있습니다. 연구가 진행됨에 따라 새로운 치료 효과가 밝혀짐에 따라 에리스로포이에틴 제제는 기존의 빈혈 관리를 넘어 신흥 의료 분야로의 적용 확대가 기대되고 있습니다.

에리스로포이에틴 제제 시장의 급격한 성장을 이끄는 요인은?

세계 에리스로포이에틴 제제 시장의 성장은 만성 신장 질환(CKD), 암, 당뇨병 등 만성질환 증가를 포함한 여러 요인에 의해 주도되고 있습니다. 전 세계에서 고령화가 진행됨에 따라 이러한 질환의 발생률은 지속적으로 증가하고 있으며, 효과적인 빈혈 치료제에 대한 수요가 증가하고 있습니다. 생물제제 개발의 발전, 특히 지속형 EPO 제제 생산 기술의 발전은 치료의 지속성을 향상시키고 투여 빈도를 감소시켜 시장 확대를 더욱 촉진하고 있습니다. 바이오시밀러의 승인 급증도 시장 성장의 중요한 원동력이 되고 있습니다. 바이오시밀러는 전 세계 의료 시스템이 브랜드 생물제제를 대체할 수 있는 비용 효율적인 대안을 찾고 있는 가운데, 바이오시밀러는 동등한 효능을 유지하면서 치료 비용을 크게 절감하고 신흥 시장에서의 접근성을 확대할 수 있는 대안이 되고 있습니다.

빈혈 치료 프로그램에 대한 규제의 발전과 정부 지원도 시장의 상승 추세에 더욱 기여하고 있습니다. 많은 국가들이 공공 의료 시스템에서 에리스로포이에틴 제제의 사용을 촉진하는 상환 정책이나 국가 빈혈 관리 프로그램을 도입하고 있습니다. 또한 주사형 ESA의 대안으로 저산소 유도인자 프롤릴수산화효소 억제제(HIF-PHI)의 채택이 증가하면서 치료 옵션이 다양해져 제약사들의 투자를 이끌어내고 있습니다. 또한 환자 개개인의 필요에 따라 EPO 요법을 조정하는 맞춤의료에 대한 관심이 높아지고 있는 것도 치료 성과와 시장 침투율 향상에 기여할 것으로 예측됩니다. 지속적인 연구, 새로운 치료 적응증, 생명공학 기술의 발전으로 세계 에리스로포이에틴 제제 시장은 지속적으로 확대될 것으로 예상되며, 전 세계에서 증가하는 빈혈 관련 질환의 부담에 대응할 수 있을 것으로 보입니다.

부문 :

약제 유형(에포에틴 알파, 다베포에틴 알파, 에포에틴 베타, 기타 약제 유형) 적응증(신장 질환, 혈액학, 암, 기타 적응증)

조사 대상 기업의 예

  • Amgen, Inc.
  • Biocon Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co., Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • XTL Biopharmaceuticals Ltd.

AI 통합

검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보 분석 방식을 혁신하고 있습니다.

일반적인 LLM이나 산업 특화형 SLM에 쿼리하는 방식이 아닌, Global Industry Analysts는 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 비디오 전사, 블로그, 검색엔진 조사, 그리고 방대한 양의 기업, 제품/서비스, 시장 데이터가 포함됩니다.

관세 영향 계수

이번 보고서에는 Global Industry Analysts가 예측한 본사 소재지, 생산기지, 수출입(완제품 및 OEM)에 따른 기업의 경쟁력 변화에 따라 지역 시장에 미치는 관세의 영향을 반영했습니다. 이러한 복잡하고 다면적인 시장 현실은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학을 통해 경쟁사들에게 영향을 미칠 것입니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 세계의 기타 지역

제4장 경쟁

KSA

Global Erythropoietin Drugs Market to Reach US$17.3 Billion by 2030

The global market for Erythropoietin Drugs estimated at US$13.4 Billion in the year 2024, is expected to reach US$17.3 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Epoetin-alfa, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$9.2 Billion by the end of the analysis period. Growth in the Darbepoetin-alfa segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 4.0% CAGR

The Erythropoietin Drugs market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 4.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Erythropoietin Drugs Market - Unveiling Trends & Growth Accelerators

Why Are Erythropoietin Drugs Critical in Modern Healthcare?

Erythropoietin (EPO) drugs play a pivotal role in the treatment of anemia associated with chronic kidney disease (CKD), cancer, and other medical conditions that impair red blood cell production. These drugs mimic the natural hormone erythropoietin, which is primarily produced by the kidneys and stimulates bone marrow to generate red blood cells. By increasing red blood cell counts, erythropoietin drugs help improve oxygen delivery to tissues, reducing fatigue and enhancing overall patient well-being. Over the years, their usage has expanded beyond nephrology to include oncology, neurology, and even sports medicine, making them one of the most versatile biologic drugs in modern medicine.

The demand for erythropoietin drugs has surged due to the rising prevalence of CKD and cancer-related anemia, particularly in aging populations. Additionally, patients undergoing chemotherapy often experience severe anemia, necessitating the use of EPO drugs to mitigate treatment-related side effects. With advancements in biotechnology, newer formulations such as darbepoetin alfa and methoxy polyethylene glycol-epoetin beta have been developed, offering longer half-lives and reduced dosing frequencies. Furthermore, biosimilar erythropoietin drugs have gained significant traction, providing cost-effective alternatives to branded biologics and expanding accessibility for patients worldwide. As the global burden of anemia-related diseases continues to grow, erythropoietin drugs remain a cornerstone of effective anemia management.

How Are Innovations Transforming the Erythropoietin Drug Market?

Innovation in erythropoietin drugs has been driven by the need for more efficient, long-lasting, and cost-effective treatments. One of the most significant advancements is the development of second-generation and third-generation EPO drugs, which feature extended half-lives and improved efficacy. For example, darbepoetin alfa has been engineered with additional carbohydrate chains, allowing for less frequent dosing compared to traditional recombinant human erythropoietin (rHuEPO). Similarly, methoxy polyethylene glycol-epoetin beta offers prolonged activity, reducing the need for frequent injections and improving patient compliance. These next-generation drugs are revolutionizing anemia treatment, particularly for CKD and cancer patients who require long-term therapy.

Another major breakthrough is the rise of erythropoiesis-stimulating agents (ESAs) that work through alternative mechanisms, such as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). These oral drugs, unlike traditional EPO injections, stimulate endogenous erythropoietin production, mimicking the body’s natural response to low oxygen levels. This innovation has opened new treatment avenues, especially for patients with CKD who are unable to tolerate injectable therapies. Additionally, the growing availability of biosimilar EPO drugs has significantly disrupted the market by offering affordable options without compromising efficacy. As governments and healthcare providers seek cost-effective treatment alternatives, biosimilars are expected to gain further market share, making EPO therapy more accessible worldwide.

Which Therapeutic Areas Are Driving the Demand for Erythropoietin Drugs?

Erythropoietin drugs have established a strong presence across multiple therapeutic areas, with nephrology and oncology leading the market. CKD remains the largest segment, as anemia is a common complication in patients with declining kidney function. With the increasing incidence of diabetes and hypertension-two major risk factors for CKD-the demand for erythropoietin drugs continues to rise. Patients undergoing dialysis or kidney transplants also rely heavily on EPO therapy to maintain adequate red blood cell levels, preventing severe anemia-related complications. The nephrology sector’s reliance on these drugs has solidified their place as a critical component of CKD management.

Oncology is another key driver of erythropoietin drug demand, as cancer patients frequently develop anemia due to chemotherapy-induced bone marrow suppression. By using EPO drugs, oncologists can reduce the need for blood transfusions, improving patients' quality of life and supporting continuous cancer treatment. Additionally, erythropoietin drugs are gaining traction in other medical fields, including neurology, where they are being explored for neuroprotective effects in stroke and neurodegenerative diseases. Some studies suggest that EPO drugs may enhance cognitive recovery following brain injuries, opening new possibilities for their application. As research continues to uncover novel therapeutic benefits, erythropoietin drugs are expected to expand into emerging medical areas beyond their traditional use in anemia management.

What’s Driving the Rapid Growth of the Erythropoietin Drugs Market?

The growth in the global erythropoietin drugs market is driven by several factors, including the increasing prevalence of chronic diseases such as CKD, cancer, and diabetes. As the global population ages, the incidence of these conditions continues to rise, fueling the demand for effective anemia treatments. Advances in biologic drug development, particularly in the production of long-acting EPO formulations, have further propelled market expansion by improving treatment adherence and reducing dosing frequency. The surge in biosimilar approvals has also played a crucial role in driving market growth, as healthcare systems worldwide seek cost-effective alternatives to branded biologics. Biosimilars have significantly reduced treatment costs while maintaining comparable efficacy, expanding accessibility in emerging markets.

Regulatory advancements and government support for anemia treatment programs have further contributed to the market’s upward trajectory. Many countries have introduced reimbursement policies and national anemia management programs that promote the use of erythropoietin drugs in public healthcare systems. Additionally, the increasing adoption of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) as an alternative to injectable ESAs is diversifying treatment options and attracting investments from pharmaceutical companies. The growing emphasis on personalized medicine, where EPO therapies are tailored to individual patient needs, is also expected to enhance treatment outcomes and market penetration. With ongoing research, new therapeutic indications, and continuous advancements in biotechnology, the global erythropoietin drugs market is poised for sustained expansion, addressing the growing burden of anemia-related diseases worldwide.

SCOPE OF STUDY:

The report analyzes the Erythropoietin Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Epoetin-Alfa, Darbepoetin-Alfa, Epoetin-Beta, Other Drug Types); Application (Kidney Disorders, Hematology, Cancer, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 12 Featured) -

  • Amgen, Inc.
  • Biocon Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co., Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • XTL Biopharmaceuticals Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Erythropoietin Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Anemia Associated with Chronic Kidney Disease Boosting Demand for Erythropoietin Drugs
    • Increasing Use of Erythropoietin in Cancer Treatment for Chemotherapy-induced Anemia
    • Expansion of Therapeutic Applications Beyond Anemia to Neuroprotection and Wound Healing
    • Growing Biosimilars Market Intensifying Competition Among Erythropoietin Manufacturers
    • Consumer Awareness and Increasing Healthcare Access in Emerging Markets
    • Integration of Artificial Intelligence in Clinical Trials for Faster Drug Development
    • Rising Demand for Erythropoietin Drugs in Sports Medicine and Doping
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Kidney Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Kidney Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Kidney Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Epoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Epoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Epoetin-alfa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Darbepoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Darbepoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Darbepoetin-alfa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Epoetin-beta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Epoetin-beta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Epoetin-beta by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 25: World Erythropoietin Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • CHINA
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Erythropoietin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of World 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of World 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제